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Abstract
Background RNA interference provides a powerful technology for specific
gene silencing. Therapeutic applications of small interfering RNA (siRNA)
however require efficient vehicles for stable complexation, protection, and
extra- and intracellular delivery of these nucleic acids. Here, we evaluated
the potential of transferrin (Tf)-associated liposomes for siRNA complexation
and gene silencing.
Methods Cationic liposomes composed of DOTAP : Cholesterol associated
with or without transferrin (Tf) were complexed with siRNA at different
lipid/siRNA charge ratios. Complexation and protection of siRNA from
enzymatic degradation was assessed with the PicoGreen intercalation assay
and gel electrophoresis. Cellular internalization of these siRNA Tf-lipoplexes
was detected by confocal microscopy. Luciferase assay, immunoblot and
fluorescence-activated cell sorting (FACS) analysis were used to evaluate
reporter gene silencing in Huh-7 hepatocarcinoma and U-373 glioma cells.
c-Jun knockdown in HT-22 cells was evaluated by quantitative real-time
polymerase chain reaction (RT-PCR). Cytotoxicity of the siRNA complexes
was assessed by Alamar blue, lactate dehydrogenase and MTT assays.
Results Complexation of siRNA with the cationic liposomes in the presence
of Tf results in the formation of stable particles and prevents serum-mediated
degradation. Confocal microscopy showed fast cellular internalization of the
Tf-lipoplexes via endocytosis. In the GFP glioma cells Tf-lipoplexes showed
enhanced gene silencing at minimum toxicity in comparison to Tf-free
lipoplexes. Targeting luciferase in the hepatocarcinoma cell line resulted
in more than 70% reduction of luciferase activity, while in HT-22 cells 50%
knockdown of endogenous c-Jun resulted in a significant protection from
glutamate-mediated toxicity.
Conclusions Cationic liposomes associated with Tf form stable siRNA
lipoplexes with reduced toxicity and enhanced specific gene knockdown
activity compared to conventional lipoplexes. Thus, such formulations may
constitute efficient delivery systems for therapeutic siRNA applications.
Copyright  2007 John Wiley & Sons, Ltd.
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Introduction
RNA interference (RNAi) is an important biological
process and a useful tool to modulate gene expression
with implications in several fields, such as functional
genomics, drug validation, and even transgenic design
[1–4]. The discovery of RNAi has generated enthusiasm
within the scientific community and its application for
therapeutic purposes has been tested recently in several
disease models that include viral infection [5–7], cancer
[8–11], acute hepatitis [12,13], and dominantly inherited
genetic disorders [14–16].
Sequence-specific post-transcriptional gene silencing
is mediated by small interfering RNAs (siRNAs), about
21–23 nucleotides long, that originate from long double-
stranded (ds)RNAs of endogenous or exogenous origin,
after cleavage by a type III ribonuclease named DICER
[17]. siRNA fragments are incorporated into a nuclease
complex called RISC (RNA-induced silencing complex)
where the RNA is unwound and one of the strands is
released [18]. The active RISC complex is responsible for
targeting and cleaving mRNA that is complementary to
the siRNA [19].
RNAi holds a pronounced therapeutic potential, since
application of siRNA may allow highly specific targeting
of selected proteins without the common adverse effects
of less specific drug-based therapies or the dangers of
viral gene therapy. In addition, double-stranded siRNA
is more stable and allows effective knockdown at lower
concentrations and for longer time periods compared
to single-stranded oligonucleotides used in antisense
technology [20]. In addition, RNAi acts primarily in the
cytoplasm, which is easier to access than the nucleus,
thus avoiding one of the major obstacles of plasmid
DNA delivery – the nuclear barrier. Nevertheless, the
development of RNAi-based therapeutics faces some of
the same challenges which have delayed the successful
application of conventional gene therapy, including the
design of suitable vectors able to cross the gap between
cell culture and animal models, thus allowing an efficient
and stable siRNA delivery in vivo. Currently, chemically
synthesized siRNA is most effectively introduced into cells
using electroporation [21,22] or commercially available
lipid reagents, but these methods are poorly suited for
in vivo delivery, due to their lack of efficiency or significant
non-specific gene silencing [23]. So far, the vast majority
of in vivo studies employing RNA interference technology
have used high doses of non-modified naked siRNAs,
usually delivered through hydrodynamic injection [24].
Although promising, this method has raised several
safety concerns associated with the high siRNA dose
necessary to achieve efficient silencing. Recent studies
suggest that high shRNA concentrations can overwhelm
the endogenous machinery responsible for siRNA and
miRNA mediated silencing, and then induce considerable
cytotoxic effects [25]. Although no such concerns have
been reported regarding siRNAs, low concentrations of
both siRNA and delivery agents should be preferred, in
order to avoid activation of the mammalian immune
system [26–28]. In this context, cationic liposome carriers
can help to significantly reduce necessary siRNA doses
for efficient gene silencing by enhancing siRNA stability
in the serum and improving cellular uptake. These
lipid-based formulations also present a high degree
of versatility that allows modifications which result
in a significant increase of their targeting specificity
and transfection capacity [29–32]. In this regard,
DOTAP : Cholesterol/DNA complexes have been widely
explored by us for both in vitro [30,33] and in vivo
[29] gene therapy applications, mainly due to their
capacity to mediate transfection in the presence of serum.
The resistance to inhibition by serum exhibited by this
formulation is related to the presence of cholesterol,
a helper lipid, that can potentially reduce undesired
interactions of lipoplexes with serum proteins, hence
increasing their stability in biological systems [34–37].
Transfection activity can be enhanced by the association
of targeting ligands such as antibodies, peptides or
proteins to the complexes, which exploit the diversity
of receptors existent at the surface of each cell type
[31,32,38]. One useful cell-binding ligand is transferrin
(Tf), an iron-transporting protein, which interacts with
receptors ubiquitously expressed in various tissues [39].
Targeting Tf receptors has been successfully applied for
DNA delivery by using antibodies against these receptors
[40,41], by linking the ligand to pegylated liposomes [42],
or by associating the protein to cationic liposomes through
electrostatic interactions [32,38,43]. In this regard, we
and others have recently demonstrated that association
of Tf to lipoplexes significantly enhances transfection
efficiency by promoting lipoplex internalization in a
large variety of cells, including dividing and non-dividing
cells, e.g. neurons [29,30,32,38,43–45]. In addition, we
have reported that Tf can trigger cytoplasmic delivery
of the carried nucleic acids through destabilization of
the endosomal membrane under acidic conditions, thus
further improving the transfection process [32,33].
However, despite the widespread use of protein-
associated cationic liposomes, there are still very few
reports concerning their application for siRNA delivery.
The present study aims to show that Tf-lipolexes, well
known for their ability to deliver DNA in vitro and in vivo,
can also be optimized for siRNA delivery, resulting both
in efficient levels of intracellular siRNA and promising
gene silencing effects. We applied the optimized Tf-
lipoplexes to transfer siRNA targeting stably expressed
reporter genes such as the green fluorescent protein
(GFP) and firefly luciferase in U-373 glioblastoma and
Huh-7 hepatocarcinoma cells, as well as siRNA targeting
the endogenous transcription factor c-Jun in HT-22
immortalized mouse hippocampal neurons. Since c-Jun
plays a key role in neuronal cell death in a wide variety
of injury models relevant to neurodegenerative diseases
[46], we finally addressed the therapeutic potential of
c-Jun siRNA-Tf-lipoplexes against glutamate toxicity in
the HT-22 neuronal cell line.
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Materials and methods
Materials
The cationic lipid 1,2 dioleoyl-3(trimethylammonium)
propane (DOTAP) and cholesterol (Chol) were pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA).
Iron-saturated human transferrin (Tf) was obtained
from Sigma (St. Louis, MO, USA). The anti-GFP
siRNA (5′-GCAAGCUGACCCUGAAGUUCAU-3′) and Cy3-
labeled non-specific siRNA sequence were purchased
from Ambion (Austin, TX, USA). The anti-luciferase
siRNA (luciferase Gl2 duplex) and the non-silencing
siRNA used as control were obtained from Dhar-
macon (Lafayette, CO, USA). The anti-c-Jun siRNA
(5′-AGTCATGAACCACGTTAAC-3′) was obtained from
Thermo Byoproducts. All the other chemicals were
obtained from Sigma unless stated otherwise.
Liposome and complex preparation
Cationic liposomes composed of DOTAP : Chol (1 : 1 molar
ratio) were prepared as previously described by Campbell
[47]. Briefly, a mixture of the appropriate amounts of
lipids, from stock solutions in chloroform, was dried under
nitrogen in order to obtain a thin lipid film. The film was
dissolved in 100 µl of ultrapure ethanol and the resulting
ethanol solution was injected in 900 µl of HBS buffer
(Hepes-buffered saline solution, 20 nM Hepes, 100 mM
NaCl, pH 7.4) continuously maintained under vortex,
employing a 250 µl Hamilton syringe. The resulting MLV
(multilamellar vesicles) were sonicated briefly to obtain
SUV (small unilamellar vesicles), diluted with HBS to a
final lipid concentration of 1 mg/ml, and stored at 4 ◦C
until use.
Cationic liposome/siRNA complexes were prepared by
sequentially mixing 100 µl of HBS buffer with liposomes
(whose volume was dependent on the desired (+/−)
charge ratio) and with 10 µl of a 5 pmol/µl siRNA
solution. The mixture was further incubated for 15 min at
room temperature.
Tf-lipoplexes were prepared by pre-incubating cationic
liposomes with iron-saturated human Tf (32 µg/µg of
siRNA) for 15 min, before mixing 10 µl of siRNA solution
and further incubating the mixture for 15 min, at room
temperature. All formulations were used immediately
after preparation.
PicoGreen intercalation assay
The accessibility of the fluorescent intercalating probe
PicoGreen (Molecular Probes, Carlsbad, CA, USA) to
the siRNA associated with the cationic liposomes was
evaluated at 37 ◦C, for 2 min, in a SPEX Fluorolog
spectrometer (SPEX Industries, Edison, NJ, USA). Briefly,
PicoGreen fluorescence was detected at excitation and
emission wavelengths of 480 and 520 nm, respectively.
The sample chamber was equipped with a stirring device
and the temperature was controlled with a feedback-
regulated circulating water bath. The fluorescence scale
was calibrated such that the initial fluorescence of
PicoGreen (1 ml of 1 : 200 solution added to the cuvette
containing 1 ml of HBS) was set as residual fluorescence.
The value of fluorescence obtained upon addition of
400 ng of siRNA (control) minus residual fluorescence
was set as 100%. Plain complexes or Tf-lipolexes,
containing 400 ng of siRNA in 1 ml HBS buffer, were
added to the cuvette containing 1 ml of PicoGreen
solution. The amount of siRNA available to interact with
the probe was calculated by subtracting the values of
residual fluorescence (PicoGreen without siRNA) from
those obtained for each measurement, and expressed
as a percentage of the control that contained naked
siRNA only, according to the following formula: %
free siRNA = (PicoGreen fluorescencecomplexes/PicoGreen
fluorescencenaked siRNA) × 100. The proper controls were
performed in order to exclude a possible non-specific
decrease in PicoGreen fluorescence due to the presence
of lipid or protein.
Protection from RNase and
serum-mediated degradation
Resistance of complexes to RNase and serum-mediated
degradation were determined by electrophoresis and
ethidium bromide staining. Complexes containing 500 ng
of siRNA were submitted to 30 min incubation at 37 ◦C,
in the presence of 0.1 U/µl RNaseV1 (Ambion), or
to different incubation periods in 50% mouse serum
(Jackson Immuno Research Laboratories Inc., West Grove,
PA, USA) in HBS buffer. Parallel experiments were
performed by incubating the samples under the same
experimental conditions in the absence of serum or RNase
V1 or in the presence of heat-inactivated mouse serum.
After siRNA extraction using Tri-Reagent (Sigma)
and precipitation overnight at −20 ◦C, the resuspended
samples were analyzed in a 15% polyacrylamide gel for
2 h, applying a voltage of 110 V. The gel was stained
for 5 min in ethidium bromide and the intensity of the
siRNA bands analyzed using the Versa Doc imaging system
(Bio-Rad, Hercules, CA, USA).
Measurement of particle size and
zeta-potential
Particle size of Tf-lipolexes was measured by laser-
light scattering using a Malvern Zetasizer 3000HS
(Malvern Instruments, Worcestershire, UK). The Tf-
lipolexes containing 10 µg siRNA were prepared at 3/2
or 2/1 lipid/siRNA (+/−) charge ratios and diluted
to a final volume of 2 ml with HBS buffer containing
10% serum. For evaluation of the zeta-potential the Tf-
lipolexes were further diluted in 10 mM NaCl to give a
final siRNA concentration of 2 µg/µl. Zeta-potential and
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particle size of the formulations were determined in at
least two independent experiments, each with five or ten
independent measurements, respectively.
Generation of U-373/eGFP and
Huh-7/eGFPLuc cell lines
For the generation of stably transfected cells, the vectors
pEGFP or pEGFPLuc (Clontech, Palo Alto, USA) were
linearized using the restriction enzyme Dra III, and
U-373 or Huh-7 cells were transfected with the respective
linearized vectors using linear polyethylenimine 22 kDa
(PEI22) polyplexes generated in HEPES-buffered saline
+ HEPES-buffered glucose 1 : 1 (HBS1/2: 75 mM NaCl,
2.5% glucose, 20 mM HEPES, pH 7.2) with a PEI nitrogen
to DNA phosphate (N/P) ratio of 6/1. Cells were incubated
in fresh medium for 72 h and then selected with 60
to 400 µg/ml G418 (geneticin; Invitrogen, Karlsruhe,
Germany). After several days, surviving cells were seeded
at low densities into six-well plates in order to generate
separate colonies. Single cell clones were then isolated
and expanded. The generated clones were analyzed
for the percentage of GFP-positive (eGFPLuc stably
transfected) cells. Clones with the highest amount of
GFP-positive cells were then further selectively grown
under the above described selective conditions and this
procedure was repeated until all cells were positive
for GFP. These stably transfected U-373/eGFP or Huh-
7/eGFPLuc cells were then used for siRNA delivery
experiments.
Cell culture and siRNA delivery
U-373 cells (glioblastoma-derived cell line) stably express-
ing GFP, Huh-7 cells (hepatocarcinoma-derived cell line)
stably expressing a GFP-Luc fusion protein, and HT-22
cells (immortalized mouse hippocampal neurons [48])
were incubated at 37 ◦C in an humidified atmosphere
containing 5% CO2. Both U-373 and HT-22 cell lines
were maintained in DMEM (Dulbecco’s modified Eagles’s
medium) (Sigma), while Huh-7 cells were maintained in
DMEM/Ham’s F12 (GIBCO, Paisley, Scotland). Both cul-
ture media were supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (GIBCO), 100 µg/ml strepto-
mycin and 1 U/ml penicillin. In the case of the U-373
cell line, DMEM was also supplemented with 24 µl/ml of
the selection antibiotic Geneticin (GIBCO) for a final
concentration of 50 mg/ml.
Twenty-four hours before any experiment, U-373,
Huh-7 and HT-22 cells were plated at a density of
25 000 cells/cm2. Immediately before addition of the
complexes, the cells were washed and the medium
was replaced with fresh medium, and 100 µl of plain
or Tf-lipolexes prepared at different lipid/siRNA (+/−)
charge ratios were added to the cells to a final siRNA
concentration of 1 µM. As a positive control for siRNA
delivery, Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) diluted in OPTIMEM (GIBCO) was used according
to the manufacturer’s instructions. In addition, a non-
silencing siRNA sequence was used in parallel with
the anti-GFP, anti-luciferase or anti-c-Jun sequences, in
order to ensure that the decrease in protein levels was
attributable to the selected siRNA and not to the vector
per se. After 4 h of incubation the medium was replaced
and the cells were further incubated for different periods
of time, before evaluation of siRNA transfection.
Epifluorescence and confocal
microscopy studies
Following siRNA transfection, the number of GFP-positive
cells was determined by epifluorescence microscopy
using a Axiovert 200 microscope (Zeiss, Thornwood,
NY, USA), equipped with the 20× objective. Briefly,
48 h after complex delivery, U-373 cells were washed
with phosphate-buffered saline (PBS), fixed with 4%
paraformaldehyde for 15 min at room temperature,
stained with the fluorescent DNA-binding dye Hoechst
33342 (1 µg/ml), rinsed again with PBS and mounted
in Vecta Shield mounting medium (Vecta Laboratories
Inc., Burlingame, CA, USA) for subsequent analysis. For
each experimental condition, the number of blue nuclei
and green cells was counted in nine separate coverslips
(an average of 300 cells per coverslip) and results were
expressed as the percentage of GFP-positive cells of
total cell number per field. In addition, for analysis of
cellular uptake of siRNA and Tf-lipoplexes, Huh-7 cells
were incubated for 4 h with naked or complex-associated
Cy3-labeled siRNAs. Following incubation, the cells were
washed and mounted in PBS and immediately visualized
by confocal microscopy. All observations were made using
a Axiovert confocal scanning microscope (Zeiss, Jena,
Germany), under the 60× oil immersion objective.
Fluorescence-activated cell sorting
(FACS) analysis
Flow cytometric data were obtained in a Cyan MLE flow
cytometer (DaKoCytomation, Copenhagen, Denmark).
Seventy-two hours after siRNA delivery, U-373 cells were
washed with PBS and treated with trypsin (10 min,
37 ◦C) to allow detachment from the wells. After
trypsin inactivation with medium, cells were centrifuged
at 1000 rpm and the supernatant was removed. The
remaining pellet was resuspended in 600 µl PBS with
4% paraformaldehyde and placed on ice until further
analysis. To discriminate between viable and dead cells
and to exclude doublets, cells were appropriately gated by
forward/size scatter and pulse width and 1 × 104 gated
events were collected per sample. The FITC bandpass filter
was used in emission detection. Tf-complex-mediated
GFP silencing was expressed as percentage of GFP mean
fluorescence in controls.
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Western blot analysis
Forty-eight hours after siRNA delivery, protein extracts
were obtained from U-373 cells using a lysis buffer
containing protease inhibitors (Sigma). Protein content
was determined using the Bio-Rad protein quantification
kit and 20 µg of total protein were ressuspended in
loading buffer (20% glycerol, 10% sodium dodecyl sulfate
(SDS), 0.1% bromophenol blue), incubated for 2 min at
95 ◦C, and loaded onto a 10% polyacrylamide gel. After
electrophoresis the proteins were blotted onto a PVDF
membrane according to standard protocols. After blocking
in 5% non-fat milk, the membrane was incubated with
an anti-GFP antibody (1 : 1000) (Roche, Indianapolis,
IN, USA) overnight at 4 ◦C, and with the appropriate
secondary antibody (1 : 20000) (Amersham, Uppsala,
Sweden) for 2 h at room temperature. Equal protein
loading was shown by reprobing the membrane with an
anti-α-tubulin antibody (1 : 10000) (Sigma) and with the
same secondary antibody. After this incubation period,
the blots were washed several times with saline buffer
(TBS/T: 25 mM Tris-HCl, 150 mM NaCl, 0.1% Tween
and 5 mg/ml non-fat powder milk) and incubated with
ECF (alkaline phosphatase substrate; 20 µl of ECF/cm2
of membrane) for 5 min at room temperature and then
submitted to fluorescence detection at 570 nm using a
Storm-860 (Molecular Dynamics, CA, USA). For each
membrane, the analysis of band intensity was performed
using the Quantity One software (Bio-Rad).
Luciferase activity evaluation
Luciferase gene silencing, mediated by Tf-lipoplexes, was
measured in protein extracts from Huh-7 cells using a
luciferase detection kit, according to the protocol provided
by the manufacturer (Promega, Madison, WI, USA).
Briefly, 48 h after delivery of Tf-lipolexes, cells were lysed
with luciferase lysis buffer (Promega) for 15 min at room
temperature. Then 20 µl of protein extract were removed
from each well and added to 100 µl of luciferase assay
buffer, containing luciferin. Luciferase activity, measured
as relative light units (RLU), was immediately evaluated
in a SpectraFluorPlus luminometer (Tecan, Ma¨nnedorf,
Switzerland) and the data were expressed as percentage
of control (untreated cells).
Cell viability assays
Following siRNA transfection of U-373 cells under
the different experimental conditions, cell viability was
quantified by a modified Alamar blue assay [49]. The
assay measures the redox capacity of cells due to the
production of metabolites as a result of cell growth, and
allows the determination of viability over the culture
period without detachment of adherent cells. Briefly,
1 ml of 10% (v/v) Alamar blue dye in complete DMEM
medium was added to each well 24 or 48 h following
the initial incubation period with Tf-lipoplexes (4 h).
After 2 h of incubation at 37 ◦C, 150 µl of supernatant
were collected from each well and transferred to
96-well plates. The absorbance at 570 and 600 nm was
measured in a microplate reader (SLT Lab instruments
Spectra). Cell viability was calculated as percentage of
control cells using the formula: (A570 − A600) of treated
cells × 100/(A570 − A600) of control cells.
Alternatively, plasma membrane integrity after siRNA
transfection was evaluated using the lactate dehydroge-
nase (LDH) assay. This assay monitors the conversion of
NADH into NAD+ by LDH at 340 nm. The LDH released
into the extracellular medium by damaged cells was
expressed as a percentage of the total LDH activity in the
cells (% LDH released = extracellular LDH/(extracellular
LDH + intracellular LDH)).
Viability of HT-22 cells, following delivery of ther-
apeutic (anti-c-Jun) siRNAs and glutamate-induced
toxicity, was determined in 96-well plates by 3-
(4,5dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bro-
mide (MTT) reduction. Forty-eight hours after Tf-complex
delivery, glutamate was added to a final concentration of
2 mM. After 18 h of glutamate exposure, the cells were
washed with fresh growth medium and further incubated
with MTT (0.25 mg/ml) for 2 h at 37 ◦C. The reaction
was terminated by adding dimethyl sulfoxide solution
and the absorbance was determined at 590 and 630 nm
in an ELISA microplate reader (Spectra FluorPlus; Tecan,
Durham, NC, USA). Cell viability was calculated as per-
centage of control cells using the formula: (A590 − A630)
of treated cells × 100/(A590 − A630) of control cells.
Extraction of RNA and cDNA synthesis
For each condition, total RNA was extracted from
1 × 106 HT-22 cells using the RNeasy Mini kit (Quiagen,
Hilden, Germany), according to the manufacturer’s
recommendations for cultured cells. Briefly, after cell
lysis, the total RNA was adsorbed to a silica matrix,
washed with the recommended buffers, and eluted with
40 µl of RNase-free water by centrifugation. After RNA
quantification, cDNA conversion was performed using
the Superscript III First Strand synthesis kit (Invitrogen,
Karlsruhe, Germany), according to the manufacturer’s
instructions. For each sample, cDNA was produced from
0.5 µg of total RNA in an iQ5 thermocycler (Bio-Rad),
by applying the following protocol: 10 min at 25 ◦C,
30 min at 55 ◦C and 5 min at 85 ◦C. After cDNA synthesis,
a 30 min incubation period with RNase H at 37 ◦C
was performed in order to remove any remaining RNA
contamination. Finally, the cDNA was diluted 1 : 3 with
RNase-free water prior to quantification by quantitative
real-time polymerase chain reaction (QRT-PCR).
QRT-PCR
QRT-PCR was performed in an iQ5 thermocycler (Bio-
Rad) using 96-well microtiter plates and the iQ SYBR
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Green Supermix kit (Bio-Rad). The primers for the
target gene (c-Jun) and the two tested house-keeping
genes (GADPH and HPRT) were pre-designed by Quia-
gen (QuantiTect Primer, Quiagen). A master mix was
prepared for each primer set, containing a fixed volume
of SYBR Green Supermix and the appropriate amount of
each primer, to yield a final concentration of 150 nM.
For each reaction, 20 µl of master mix were added to
5 µl of template cDNA. All reactions were performed in
duplicate (two cDNA reactions per RNA sample) at a final
volume of 25 µl per well, using the iQ5 Optical System
software (Bio-Rad). The reaction conditions consisted of:
enzyme activation and well-factor determination at 95 ◦C
for 1 min and 30 s followed by 40 cycles at 95 ◦C for
10 s (denaturation), 30 s at 55 ◦C (annealing) and 30 s
at 72 ◦C (elongation). The melting curve protocol started
immediately after amplification and consisted of 1 min
heating at 55 ◦C followed by 80 steps of 10 s, with a
0.5 ◦C increase in temperature at each step. Threshold
values for threshold cycle determination (Ct) were gen-
erated automatically by the iQ5 Optical System software.
The percentage of c-Jun knockdown was determined by
the Ct method, using HPRT as reference gene, accord-
ing to the formulas: Ct(c−Jun siRNA) = Ct(c−Jun gene) −
Ct(HPRT gene);Ct(Mut siRNA) = Ct(c−Jun gene) − Ct(HPRT gene);
Ct = Ct(c−Jun siRNA) − Ct(Mut siRNA); % knockdown
= 100% − (2−Ct × 100). The Ct value indicates
the changes in RNA transcription caused by treatment
with anti-c-Jun siRNAs, normalized to RNA transcription
changes in cells treated with Mut siRNAs. When positive,
the Ct value indicates downregulation of the target
mRNA.
Statistical analysis
All data are presented as means ± standard deviation (SD)
of at least three independent experiments, each performed
at least in triplicate. One way analysis of variance
(ANOVA) combined with the Tukey posthoc test was
used for multiple comparisons in cell culture experiments.
Statistical differences are presented at probability levels
of p < 0.05, p < 0.01 and p < 0.001.
Results
Characterization of cationic
liposome/siRNA lipoplexes
The PicoGreen intercalation assay was applied for
monitoring complex formation of siRNA and cationic
liposomes, composed of DOTAP and cholesterol at
increasing lipid/siRNA charge ratios and in the presence
or absence of transferring (Tf).
As shown in Figure 1, a significant quenching of the
PicoGreen fluorescence was achieved at the lipid/siRNA
charge ratio of 3/2 (+/−), this being almost complete
for higher charge ratios, which indicates a very high
degree of siRNA complexation (approximately 90%) by
cationic liposomes, in the absence or presence of Tf.
These results demonstrate that complexes can be formed
through electrostatic interactions between siRNA and
cationic liposomes, although an excess of cationic lipid
is required to ensure efficient nucleic acid protection.
It is interesting to note that association of Tf to the
cationic liposomes does not result in a significant increase
of PicoGreen fluorescence over that observed for plain
lipoplexes, which suggests that its presence does not lead
to complex destabilization.
To examine stable binding and protection of siRNA
in the lipoplexes under conditions that can mimic
those in vivo, further measurements were performed
after incubating both plain and Tf-lipoplexes in the
presence of RNase V1 (0.1 U/µl) (Figure 2a) or mouse
serum (Figures 2b and 2c). Following a 30 min or 4 h
incubation period, respectively, the siRNA present in the
mixtures was recovered and analyzed in a polyacrylamide
gel stained with ethidium bromide. Both plain and Tf-
lipoplexes significantly protected siRNA from RNase V1
and serum-mediated degradation, whereas naked siRNA
was almost completely degraded, in both cases, after
a short incubation period (Figures 2a and 2b). These
results clearly indicate that the presence of cationic
lipid is crucial to confer protection of siRNA molecules
against serum nucleases. The observation that naked
siRNA samples remained almost intact upon incubation
with heat-inactivated serum suggests that the degradation
observed in the presence of serum was of enzymatic origin.
Moreover, results from parallel experiments carried out
with longer incubation periods in the presence of serum
(Figure 2c) indicate that the protection effect mediated
Figure 1. siRNA binding in plain or Tf-associated lipoplexes.
DOTAP :Chol liposomes were complexed with 400 ng of siRNA
in the presence or absence of transferrin (Tf) followed by
incubation with the fluorescent probe PicoGreen. Relative
fluorescence is presented as percentage of the control obtained
with 400 ng naked siRNA. The percentage represents the fraction
of siRNA in the sample available for PicoGreen interaction.
Results are presented as mean values ± SD from triplicates and
are representative of three independent experiments
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Figure 2. Stability of siRNA in plain or Tf-associated lipoplexes
exposed to RNase V1 and mouse serum. Plain lipoplexes or
Tf-lipoplexes containing 500 ng siRNA were incubated with
RNase V1 or complete mouse serum. After the indicated
incubation periods, siRNA was extracted and analyzed by
electrophoresis in a 15% polyacrylamide gel and subsequent
staining of the gel with ethidium bromide was performed.
Naked siRNA, plain lipoplexes or Tf-lipoplexes prepared at
a 3/2 lipid/siRNA charge ratio were incubated for 30 min in
the presence or absence of (a) RNase V1 (0.1U/µl) or for 4 h
(b) in normal or heat-inactivated mouse serum. (c) In parallel
experiments, naked siRNAs and Tf-lipoplexes were incubated for
1 h, 24 h and up to 48 h in the presence or absence of mouse
serum. The results are representative of three independent
experiments
by Tf-lipoplexes is still present after 48 h of exposure
to serum, which illustrates the high stability of these
complexes over days.
In order to further characterize Tf-lipoplexes, zeta-
potential and particle size of the two most promising
formulations (3/2 and 2/1 lipid/siRNA (+/−) charge
ratios) were evaluated in the presence of serum. Although
both formulations presented a negative surface charge,
i.e. −27.5 ± 3.1 mV and −7.0 ± 4.8 mV at charge ratios
of 3/2 and 2/1, respectively, Tf-lipoplexes prepared at
the 2/1 charge ratio exhibited a zeta-potential value very
close to neutrality, which may contribute to the significant
difference observed in the size of both formulations. The
negatively charged Tf-lipoplexes, prepared at the 3/2
charge ratio, exhibited a size of 328 ± 64 nm, whereas
the nearly neutral particles, prepared at the 2/1 charge
ratio, were significantly larger, i.e. 926 ± 47 nm. This
may be attributed to reduced electrostatic repulsions
at charge ratios of 2/1 with a consequent increase in
particle aggregation compared to the negatively charged
3/2 lipoplexes, which may contribute to differences in
siRNA delivery and biological activity.
Cellular uptake of fluorescently labeled
siRNAs
The internalization of Tf-lipoplexes was monitored in
Huh-7 cells by confocal microscopy, using Cy3-labeled
non-silencing siRNA. The results presented in Figure 3
reveal that 4 h after the delivery of Cy3-labeled Tf-
complexes, prepared at 2/1 and 4/1 lipid/siRNA charge
ratios (Figures 3a and 3b, respectively), fluorescent
particles were found to be located within very large
intracellular vesicles. In contrast, the delivery of a similar
amount of naked Cy3-labeled siRNAs (Figure 3c) did not
allow detection of red fluorescence within the cells or
even in the extracellular medium, suggesting that siRNA
degradation or removal upon washing occurs during the
incubation period with the cells.
Gene silencing efficiency
It has been demonstrated that Tf is highly effective in
promoting lipoplex-mediated transfection in various cell
lines and primary cell cultures [30,32,38,43]. Therefore,
we evaluated whether this strategy would also result in
an enhancement of siRNA transfer efficiency. Figure 4
illustrates the percentage of GFP-expressing U-373 cells,
Figure 3. Uptake of naked or Tf-lipoplex associated Cy3-siRNAs in Huh-7 cells. Huh-7 cells were plated 1 day before siRNA delivery
and rinsed with DMEM supplemented with 10% FBS immediately before delivery of Tf-lipoplexes. DOTAP :Chol liposomes were
pre-incubated in the presence of Tf (32 µg/µg siRNA), complexed with 50 pmol of Cy3-labeled non-silencing siRNA at 2/1 or 4/1
lipid/siRNA (+/−) charge ratios, and added to the cells for 4 h. In parallel experiments, cells were incubated with the same amount
of siRNAs in the absence of liposomes for the same period. After 4 h, the cells were rinsed twice with PBS and immediately observed
by confocal microscopy. The panels show representative images at 600× magnification of cells treated with (a) 2/1 lipid/siRNA
Tf-lipolexes, (b) 4/1 lipid/siRNA Tf-lipolexes, and (c) naked Cy3-siRNA. Results are representative of two independent experiments
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Figure 4. Effect of transferrin association to DOTAP :Chol liposomes on gene silencing in U-373 cells. U-373 cells stably expressing
GFP were plated 1 day before siRNA delivery and rinsed with DMEM containing 10% FBS immediately before complex delivery.
DOTAP :Chol liposomes pre-incubated in the presence or absence of Tf (32 µg/µg siRNA) were complexed with 50 pmol of anti-GFP
siRNA at the indicated lipid/siRNA charge ratios and added to the cells to a final siRNA concentration of 100 nM. After 4 h incubation,
the medium was replaced with fresh medium and the cells were incubated for a further 48 h before evaluation of GFP knockdown by
epifluorescence microscopy. (a) The number of GFP-expressing cells is presented as percentage of untreated controls. The data are
given as mean values ± SD of triplicates and are representative of three independent experiments. ∗∗∗p < 0.001 compared to plain
lipoplexes. Representative images of (b) control cells (200×) or (c) cells treated with Tf-lipoplexes prepared at 3/2 lipid/siRNA
charge ratio (200×)
48 h after delivery of plain or Tf-lipoplexes prepared at
different lipid/siRNA charge ratios. Association of Tf to the
lipoplexes resulted in a significant enhancement of GFP
knockdown at low lipid/siRNA (+/−) charge ratios, the
best results being observed with Tf-lipoplexes prepared at
a charge ratio of 3/2.
In order to establish the average levels of protein
knockdown mediated by Tf-lipoplexes at single cell
level, GFP silencing in U-373 cells was also evaluated
using FACS analysis (Figure 5). Tf-lipoplexes, prepared at
different charge ratios and containing anti-GFP siRNA or a
non-silencing sequence (Mut siRNA), were incubated with
the cells and, 72 h following delivery, the mean intensity
of GFP fluorescence was analyzed for each condition.
The values corresponding to the percentage of GFP mean
fluorescence were compared to those obtained using the
standard commercial lipid-based reagent, Lipofectamine
2000, which is frequently employed for in vitro DNA
plasmid transfection and siRNA delivery. As illustrated in
Figure 5, approximately 45% decrease in GFP levels was
observed following siRNA delivery using Tf-lipoplexes
prepared at a charge ratio of 3/2, a result very similar to
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Figure 5. Effect of lipid/siRNA charge ratio of Tf-lipoplexes on
gene silencing in U-373 cells. U-373 cells stably expressing
GFP were plated 1 day before siRNA delivery and rinsed with
DMEM containing 10% FBS immediately before delivery of the
complexes. DOTAP :Chol liposomes were pre-incubated in the
presence of Tf (32 µg/µg siRNA) and then complexed with
50 pmol of anti-GFP or non-silencing (Mut) siRNA, at the
indicated lipid/siRNA charge ratios, and added to the cells to
a final siRNA concentration of 100 nM. After 4 h incubation,
the medium was replaced and the cells were incubated for
a further 72 h. In parallel experiments, cells were incubated
with the same amount of siRNA complexed with Lipofectamine
2000 or with DOTAP : Chol liposomes associated to Tf in the
absence of siRNA (vehicle). The results were obtained by flow
cytometry 72 h after siRNA delivery. Mean GFP fluorescence
levels in a population of 10 000 events/condition are expressed
as percentage of untreated controls (mean ± SD obtained
from triplicates) and are representative of three independent
experiments. ∗∗p < 0.01, ∗∗∗p < 0.001 compared to controls,
and #p < 0.05, ###p < 0.001 compared to cells treated with
Mut siRNA at the same lipid/siRNA charge ratio
the one obtained with Lipofectamine 2000. In contrast,
DOTAP : Chol liposomes associated with Tf (vehicle) or Tf-
lipoplexes containing non-functional siRNA (Mut siRNA)
did not decrease GFP fluorescence levels, ruling out non-
specific effects due to the vector per se or to the siRNA at
the tested concentration.
The efficiency of siRNA-mediated gene silencing was
confirmed by Western blot analysis employing both anti-
GFP siRNA (Figure 6a) and Mut siRNA (Figure 6b). As
shown in Figure 6c, among the different lipid/siRNA
charge ratios tested, the most pronounced gene silencing
(a mean decrease of 50% in GFP levels) was achieved
after delivery of anti-GFP siRNA mediated by Tf-lipoplexes
prepared at a 3/2 charge ratio, demonstrating that this
is indeed the optimal charge ratio for DOTAP : Chol Tf-
lipoplexes in U-373 cells. Gene silencing was found to
be specific, since no GFP knockdown was observed with
Mut siRNA (Figure 6d) and the levels of α-tubulin were
constant for all tested formulations.
In order to evaluate whether the gene silencing effect
observed after siRNA delivery mediated by Tf-lipoplexes
was not restricted to U-373 cells, parallel transfection
experiments were performed in hepatocarcinoma cells
(Huh-7), stably transformed to express a luciferase-GFP
Figure 6. Western blot quantification of Tf-lipoplex-mediated
GFP knockdown in U-373 cells. U-373 cells were plated 1 day
before siRNA delivery and rinsed with DMEM supplemented with
10% FBS immediately before complex delivery. DOTAP :Chol
liposomes were pre-incubated in the presence of Tf (32 µg/µg
siRNA), complexed with 50 pmol siRNA at the indicated
lipid/siRNA charge ratios, and added to the cells to a final
siRNA concentration of 100 nM. After 4 h incubation, the
medium was replaced with fresh DMEM containing 10% FBS.
After a further 48 h, GFP and α-tubulin levels were quantified
after immunoblotting of protein extracts obtained from U-373
cells treated with Tf-lipoplexes containing (a) anti-GFP or
(b) non-silencing siRNAs. (c, d) Quantification of GFP silencing
observed in (a) and (b), respectively, corrected for individual
α-tubulin signal intensity. Results are expressed as percentage
of GFP expression levels in untreated controls. ∗p < 0.05,
∗∗p < 0.01 and ∗∗∗p < 0.001 compared to control
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fusion protein. To assess the silencing efficiency mediated
by Tf-lipoplexes, the levels of luciferase gene expression
were measured 48 h after delivery of Mut siRNA or
anti-luciferase siRNA (Luc siRNA), and transfection
experiments with Lipofectamine 2000 were performed
for comparison. As shown in Figure 7, the results are
consistent with those obtained in U-373 cells, with the
major difference that the levels of luciferase silencing
in Huh-7 cells are even higher than those observed for
GFP in U-373 cells (cf. Figures 5 and 7). Moreover, the
most efficient gene silencing, taking into account the
extent and specificity of action, was not observed at
a 3/2 lipid/siRNA charge ratio (data not shown) but
rather at a 4/1 lipid/siRNA charge ratio, which may be
partially attributed to differences in the metabolic activity
of U-373 and Huh-7 cells, and thus in their endocytotic
capacity. It should be noted that some non-specific
silencing of luciferase was observed for lipid/siRNA
charge ratios higher than 4/1, as shown by the decrease
in the percentage of luciferase activity obtained when
employing Mut siRNA. Similar results were observed for
gene silencing mediated by Lipofectamine 2000, although
to a lower extent.
Overall, these results demonstrate that optimization
of lipid/siRNA charge ratios resulted in efficient and
specific gene silencing by Tf-associated siRNA/liposome
complexes.
Cytotoxicity induced by Tf-lipoplexes
To evaluate whether Tf-lipoplexes were toxic to cells,
cell viability was assessed by the Alamar blue assay, 24
and 48 h after delivery of the complexes. As shown in
Figure 8a, no significant toxicity was observed in U-373
cells, independently of the lipid/siRNA charge ratio.
Similar results were observed in Huh-7 cells for the most
efficient charge ratios (2/1 and 4/1 lipid/siRNA (+/−))
(data not shown), although some toxicity (25%) was
observed at high charge ratios (6/1 and 8/1 lipid/siRNA
(+/−)) which correlates with the non-specific effect
observed for these formulations (Figure 7). Membrane
integrity was evaluated in U-373 cells, using the LDH
assay. The results illustrated in Figure 8b show that Tf-
lipoplexes are overall well tolerated by the cells, even
when prepared at high lipid/siRNA charge ratios.
Figure 7. Effect of lipid/siRNA charge ratio of Tf-lipoplexes on
luciferase silencing in Huh-7 cells. Huh-7 cells were plated 1 day
before siRNA delivery and rinsed with DMEM supplemented
with 10% FBS immediately before delivery of the complexes.
DOTAP :Chol liposomes were pre-incubated in the presence of
Tf (32 µg/µg siRNA), complexed with 50 pmol of anti-Luciferase
or non-silencing (Mut) siRNA at the indicated lipid/siRNA charge
ratios, and then added to the cells to a final siRNA concentration
of 100 nM. After 4 h incubation, the medium was replaced and
the cells were incubated for a further 48 h. Afterwards, relative
light units (RLU) were measured in each sample and luciferase
activity calculated as percentage of activity in untreated control
cells. Mean RLU ± SD values were obtained from triplicates and
are representative of three independent experiments. ∗∗p < 0.01
and ∗∗∗p < 0.001 compared to cells treated with Mut siRNA
c-Jun silencing and HT-22 protection
mediated by Tf-lipoplexes
In order to demonstrate that Tf-lipoplexes are also able
to promote efficient gene silencing of endogenous genes,
an endogenous protein was chosen as target (c-Jun) and
a complementary siRNA was synthesized based on the
mouse c-Jun mRNA sequence. To establish the average
decrease in c-Jun mRNA levels, HT-22 immortalized
mouse hippocampal neurons were incubated with Tf-
lipoplexes prepared at the 3/2 lipid/siRNA charge
ratio and containing anti-c-Jun or non-functional Mut
siRNAs. Forty-eight hours after Tf-lipoplex delivery, c-
Jun silencing was evaluated using QRT-PCR (Table 1).
The percentage of c-Jun knockdown in this cell line was
calculated using the Ct method, as described in the
Table 1. QRT-PCR quantification of Tf-lipoplex-mediated C-Jun knockdown in HT-22 cellsa
HT-22 cells Ct C-Jun Ct HPRT Ct Ct C-Jun knockdown (%) Average C-Jun knockdown (%)
Transfected with anti – C-Jun siRNA 29.6 23.5 6.1 1.0 50 51
29.7 24.4 4.9 1.1 53
27.6 23.6 4.0 1.0 50
Transfected with Mut siRNA 28.7 23.6 5.1
28.6 24.8 3.8
26.6 23.6 3.0
aThe levels of both C-Jun and HPRT genes were determined by quantitative RT-PCR 48 h after transfection. C-Jun knockdown was evaluated by the
Ct method (n = 3) using the HPRT gene as reference gene. Results are expressed as a percentage of C-Jun expression in cells treated with Mut
siRNAs.
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Figure 8. Effect of Tf-lipoplexes on the viability and membrane
integrity of U-373 cells. U-373 cells were plated 1 day before
siRNA delivery and rinsed with DMEM supplemented with 10%
FBS immediately before delivery of Tf-lipoplexes. DOTAP :Chol
liposomes were pre-incubated in the presence of Tf (32 µg/µg
siRNA), complexed with 50 pmol of non-silencing (Mut) siRNA
at the indicated lipid/siRNA charge ratios, and added to the
cells to a final siRNA concentration of 100 nM. After 4 h
incubation, the medium was replaced with fresh DMEM with
10% FBS and the cells were incubated for a further 24 or
48 h. (a) Cell viability was determined by the Alamar blue
assay. The data are expressed as percentage of untreated
controls. (b) Membrane integrity was evaluated employing the
LDH assay. Results are expressed as the percentage of total
LDH (intracellular LDH + extracellular LDH). Mean values for
LDH activity in the medium± SD were obtained from triplicates
and are representative of three independent experiments. No
significant statistical differences were observed
Materials and methods section. In this experiment, the
mean Ct value found was 1.0, which translates into
51% of c-Jun knockdown. Moreover, two endogenous
reference genes, whose expression should not differ
between samples, were used in this study as normalization
controls. The expression levels of both the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) genes did not
differ between control (non-transfected) cells and cells
treated with Tf-complexes, which indicates that no non-
specific mRNA downregulation occurs due to the vector
per se.
C-Jun is a transcription factor that promotes cell death
through transactivation of pro-apoptotic factors after
glutamate-induced damage in neurons. Therefore, we
also investigated whether the observed c-Jun knockdown
mediated by Tf-lipolexes was sufficient to attenuate cell
death after glutamate exposure in HT-22 cells. The
results presented in Figure 9 show that HT-22 neurons
pre-treated with anti-c-Jun siRNA show 40% increase
in viability after glutamate exposure compared to non-
transfected cells or cells pre-treated with non-functional
Mut siRNA. The protective effect by c-Jun siRNA was
apparently specific, since Mut siRNA did not affect
glutamate toxicity. Altogether, the results from QRT-PCR
(Table 1) and the MTT assay (Figure 9) clearly show that
the achieved c-Jun knockdown is capable of inducing a
significant therapeutic effect in HT-22 cells, protecting
them from glutamate-mediated cell death.
Discussion
The recently discovered RNAi pathway is based on
the cytoplasmic degradation of target mRNA by small
double-stranded RNA molecules complementary to the
mRNA sequence. siRNA molecules constitute already a
Figure 9. Effect of c-Jun silencing mediated by Tf-complexes
on the viability of HT-22 cells after glutamate damage. HT-22
cells were plated 1 day before siRNA delivery and rinsed with
DMEM supplemented with 10% FBS immediately before delivery
of Tf-lipoplexes. DOTAP :Chol liposomes were complexed, in the
presence of Tf (32 µg/µg siRNA), with 25 pmol of anti-c-Jun
siRNA (c-Jun siRNA) or non-silencing siRNA (Mut siRNA) at
the 3/2 lipid/siRNA charge ratio, and added to the cells to
a final siRNA concentration of 50 nM. After 4 h incubation,
the medium was replaced with fresh DMEM with 10% FBS
and the cells were incubated for a further 48 h. After this
period transfected and non-transfected cells were treated with
2 mM glutamate and incubated for 18 h before cell viability
evaluation by the MTT assay. The data are expressed as
percentage of non-transfected and untreated controls. Mean
RLU± SD were obtained from triplicates and are representative
of three independent experiments. ∗∗∗p < 0.001 compared to
cells treated with Mut siRNA
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popular tool in the fields of functional genomics [4,50,51]
and target validation, and have recently started to be
studied as a new strategy to control gene expression in
disease models. As opposed to plasmid DNA delivery,
this process does not present the delivery hurdle of
nuclear entry which significantly hampers most of the
conventional gene therapy approaches. Also, the process
of RNA interference does not involve modifications of the
cellular genome and employs highly specific and efficient
endogenous enzymatic machinery which is ubiquitously
distributed in the mammalian organism. Nevertheless,
the successful application of the RNAi approach both
in vitro and in vivo, especially in therapeutic approaches,
depends on the development of delivery systems capable
of reaching the target cells, in a stable, non-toxic and
efficient way. Tf-associated cationic liposomes have been
successfully employed for plasmid DNA delivery not
only in cancer cells, but also in normal cells, such
as neurons, both in cell culture and in animal models
[29,30], where they mediated a significant enhancement
in transfection efficiency as compared to conventional
lipoplexes. Motivated by these results, we decided to
examine the potential of Tf-associated lipoplexes for
siRNA delivery.
While exhibiting some similarity, DNA and siRNA
present several important differences that may prove
crucial in terms of complex formation upon their
interaction with cationic lipids. Due to their small size,
synthetic siRNA molecules do not necessarily require
the same process of condensation that leads to the
collapse of plasmid DNA into nanostructures, in the
presence of a cationic agent. Instead, siRNA molecules
may retain their initial structure after interaction with
the positively charged lipid headgroups and, therefore, it
is not possible to predict siRNA/lipid interactions based
on the previous knowledge of plasmid DNA behavior.
The siRNA-specific properties may lead to the formation
of particles that do not allow complete nucleic acid
condensation, which in turn can result in degradation by
macromolecules present in the extracellular environment
and thereby in low gene silencing levels. For this reason,
we initiated our study by assessing several parameters,
such as the extent of lipid/siRNA association and the
siRNA protection efficiency conferred by the cationic
lipid, which helped predict the biological stability of
the complexes. Results from these experiments revealed
that even at low lipid/siRNA charge ratio (3/2), siRNA
associated extensively with cationic liposomes both in the
absence and presence of transferrin (Figure 1), resulting
in stable complexes capable of conferring significant
protection to the carried molecules (Figure 2), thereby
inhibiting serum-mediated siRNA degradation even after
long incubation periods (Figure 2c). The stability of
lipid-based vectors in serum is especially important
since the inhibitory effect of serum on transfection
has been one of the major drawbacks when trying to
transpose these systems from cell culture conditions
to animal models, aiming at therapeutic applications.
Serum increases the size of cationic liposomes by
inducing aggregation due to interaction of negatively
charged proteins with the lipid headgroups. Although
DOPE is usually the first choice as helper lipid for
in vitro experiments, complexes containing cholesterol
have been shown to be more active in vivo, which may
be attributed to their high stability in biological fluids,
as a consequence of a lower interaction with serum
proteins.
Results from confocal microscopy on the intracellular
uptake of Tf-lipoplexes demonstrated that for both tested
charge ratios (3/2 and 2/1 lipid/siRNA), the lipoplexes
were localized inside Huh-7 cells 4 h after delivery
(Figure 3). In contrast, after incubation with naked Cy3-
labeled siRNA, no fluorescence was observed inside or
outside the cells, which may be due to siRNA degradation
by serum enzymes present in the culture medium.
These results reinforce the need to employ vectors
capable of protecting the siRNA molecules following their
administration.
In order to evaluate the biological activity of siRNA
complexes with DOTAP : Chol liposomes we performed
a series of studies focused on the major feature of
the siRNA pathway, namely the ability to induce
gene silencing and protein knockdown. Our results
(Figures 4–7) clearly demonstrate that association of
siRNAs to Tf-containing cationic liposomes resulted in a
significant enhancement of gene silencing. This correlates
to the observed decrease in the levels of reporter
proteins, thus suggesting that an efficient knockdown
of therapeutic-relevant targets may be achieved when
employing this kind of vector. Consistent with results
from our previous studies on plasmid DNA, coating
of cationic liposomes with Tf enhances gene silencing
by siRNA as compared to plain complexes (Figure 4),
which is probably due to promotion of cellular uptake of
the Tf-lipoplexes through the endocytotic pathway and
cytoplasmic delivery of the carried siRNA molecules by
destabilization of the endosomal membrane under acidic
conditions [32].
Our observations that the optimal siRNA/lipid charge
ratio albeit always positive varied considerably between
the tested cell lines suggest that there is an ideal
charge ratio for efficient gene silencing, depending
on the cell type. As illustrated in Figures 5 and 7, a
specific downregulation upon delivery of Tf-lipoplexes
was demonstrated, which is of crucial importance for
our work to be of value for future clinical applications
[1,52].
Recently, several studies have suggested that activation
of the mammalian immune system by siRNAs is dose-
dependent [25], caused by nucleoside modifications
[27,53], or stimulated by certain nucleotide sequences
frequently found in viral RNA [54]. Careful analysis
revealed that the siRNAs employed in our study do not
contain any of the known sequences that may cause
such immune responses. Moreover, we tested the lipid
vehicle alone (liposomes associated to Tf), taking into
consideration reports concerning a possible role of lipid-
based vectors in non-specific silencing effects [28,55,56].
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As shown in Figure 5, no GFP reduction was observed
for this condition. However, at high lipid/siRNA charge
ratios a significant luciferase silencing was observed for
the Mut siRNA in Huh-7 cells (Figure 7) suggesting
that the lipid, when present at high concentrations and
associated with siRNAs, can indeed contribute to a non-
specific protein decrease [56]. This may stimulate the
activation of Toll-like receptors 7 and 8 [26,27,53,57]
and the respective downstream pathways, which lead
to expression of IFN and pro-inflammatory cytokines.
This effect was also observed with Lipofectamine 2000,
which reinforces the need to always employ the lowest
effective dose of the nucleic acid delivery agent, as
well as a non-silencing control, even when siRNA
delivery is mediated by a commercial reagent [23].
Nevertheless, this was not verified in the U-373 cells,
which indicates that these non-specific effects may
be cell-type-specific, as has been recently suggested
[58].
The toxicity assays revealed that Tf-lipoplexes were
slightly better tolerated by the cells than Lipofectamine
2000 and, notably, the toxicity of lipoplexes prepared
at low lipid/siRNA charge ratios was even negligible.
This low toxicity level was observed not only for cell
lines, but also for primary neuronal cultures (data
not shown). Moreover, recent experiments involving
siRNA delivery into neuronal cultures and after local
injection into the mouse brain have clearly shown
that Tf-lipoplexes are able to mediate high levels
of gene silencing in this type of non-dividing cells
in vitro and in vivo (Cardoso et al., manuscript in
preparation). These results are promising considering the
potential applications of Tf-lipoplexes in experimental
models of neurodegenerative disorders, where high
toxic effects and low gene silencing efficiency are
major drawbacks when employing available standard
transfection reagents.
In order to clarify the potential of Tf-lipoplexes to
mediate gene silencing of both reporter and endoge-
nous genes, and as a first approach to a possible
therapeutic application of these lipid-based vectors, we
selected the c-Jun gene as target gene and investi-
gated c-Jun knockdown in a glutamate-sensitive cell-line.
The QRT-PCR results presented in Table 1 show a sig-
nificant downregulation of c-Jun mRNA (51%) after
delivery of Tf-complexes without detectable off-target
effects.
Due to its important role as a transcription factor
in several well-described pathways of apoptotic cell
death in neurons, c-Jun is a promising target for
therapeutic applications in neurodegenerative conditions,
including glutamate-induced cell death [46]. Here,
we demonstrate that c-Jun targeting siRNA mediates
a pronounced decrease in c-Jun mRNA levels and
significantly protects neuronal cells (Figure 9) from
glutamate-induced damage, which confirms the potential
of Tf-complexes to mediate an efficient therapeutic
effect. The protective effect obtained with c-Jun siRNA
in the present model system of glutamate-mediated
neurotoxicity in vitro is well in line with protective
effects against excitotoxic neuronal death observed in
mice expressing an inactive form of c-Jun [59]. It
is important to note that, although c-Jun silencing
in HT-22 cells was approximately 50%, the protective
effect observed in this cell line was highly significant,
indicating that for this target a complete knockdown
is not necessary to obtain a relevant therapeutic
effect.
Taken together, this study demonstrates that, simi-
larly to what has been previously shown for plasmid
DNA, DOTAP : Cholestrol liposomes associated to trans-
ferrin can mediate efficient intracellular siRNA delivery.
Our findings clearly show that Tf-associated lipoplexes,
when prepared at the adequate charge ratios, pro-
mote protein silencing in vitro which, together with
previous results concerning their in vivo application
[29], suggests that they may be a promising strat-
egy to translate laboratory research to clinical applica-
tion.
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